BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignancy in Asians with hepatitis B virus infection. HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial. AIMS: We sought to determine if surveillance for HCC in a community-based clinic improve survival and, if so, identify factors that contribute to the benefit of early tumor detection. METHODS: From 1991 to 2008, alpha-fetoprotein and abdominal ultrasound examination were used as surveillance tests for HCC. The survival of HCC patients detected by surveillance was compared to patients who presented to the clinic with HCC (no surveillance). An adjusted lead-time bias interval was added to the survival time of patients who presented with HCC. RESULTS: During this period, 26 patients with surveillance developed HCC while 52 patients presented with HCC. More surveillance patients had normal levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase (p < 0.05-0.0001) and had tumors that were within Milan and University of California San Francisco (UCSF) criteria (p = 0.02-0.0001). The 1-, 3-, and 5-year survival rates were higher in surveillance patients and in those who received surgical or loco-regional therapies (p = 0.007-0.0001). On multivariate analysis, baseline independent factors predicting survival were single tumors (Hazard ratio [HR] 0.25, p = 0.0005), UCSF criteria (HR 0.29, p = 0.006), Child-Turcotte-Pugh class A (HR 0.45, p = 0.03), platelet counts per log(10) increase (HR 0.315, p = 0.04) and aspartate aminotransferase per log(10) increase (HR 5.7, p = 0.01). CONCLUSIONS: Surveillance for HCC identified patients with smaller tumor burdens and more adequate liver function who were able to receive more definitive therapies. HCC surveillance improves survival and should be included as standard of care for patients with hepatitis B.
BACKGROUND:Hepatocellular carcinoma (HCC) is a common malignancy in Asians with hepatitis B virus infection. HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial. AIMS: We sought to determine if surveillance for HCC in a community-based clinic improve survival and, if so, identify factors that contribute to the benefit of early tumor detection. METHODS: From 1991 to 2008, alpha-fetoprotein and abdominal ultrasound examination were used as surveillance tests for HCC. The survival of HCC patients detected by surveillance was compared to patients who presented to the clinic with HCC (no surveillance). An adjusted lead-time bias interval was added to the survival time of patients who presented with HCC. RESULTS: During this period, 26 patients with surveillance developed HCC while 52 patients presented with HCC. More surveillance patients had normal levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase (p < 0.05-0.0001) and had tumors that were within Milan and University of California San Francisco (UCSF) criteria (p = 0.02-0.0001). The 1-, 3-, and 5-year survival rates were higher in surveillance patients and in those who received surgical or loco-regional therapies (p = 0.007-0.0001). On multivariate analysis, baseline independent factors predicting survival were single tumors (Hazard ratio [HR] 0.25, p = 0.0005), UCSF criteria (HR 0.29, p = 0.006), Child-Turcotte-Pugh class A (HR 0.45, p = 0.03), platelet counts per log(10) increase (HR 0.315, p = 0.04) and aspartate aminotransferase per log(10) increase (HR 5.7, p = 0.01). CONCLUSIONS: Surveillance for HCC identified patients with smaller tumor burdens and more adequate liver function who were able to receive more definitive therapies. HCC surveillance improves survival and should be included as standard of care for patients with hepatitis B.
Authors: J C Sheu; J L Sung; D S Chen; P M Yang; M Y Lai; C S Lee; H C Hsu; C N Chuang; P C Yang; T H Wang Journal: Gastroenterology Date: 1985-08 Impact factor: 22.682
Authors: Adrian M Di Bisceglie; Andre C Lyra; Myron Schwartz; Rajender K Reddy; Paul Martin; Gregory Gores; Anna S F Lok; Khozema B Hussain; Robert Gish; David H Van Thiel; Zobair Younossi; Myron Tong; Tarek Hassanein; Luis Balart; Jacquelyn Fleckenstein; Stephen Flamm; Andres Blei; Alex S Befeler Journal: Am J Gastroenterol Date: 2003-09 Impact factor: 10.864
Authors: Franco Trevisani; Giulia Magini; Valentina Santi; Antonio Maria Morselli-Labate; Maria Chiara Cantarini; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnù; Gianludovico Rapaccini; Fabio Farinati; Marco Zoli; Franco Borzio; Edoardo Giovanni Giannini; Eugenio Caturelli; Mauro Bernardi Journal: Am J Gastroenterol Date: 2007-02-21 Impact factor: 10.864
Authors: John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: L Barbara; G Benzi; S Gaiani; F Fusconi; G Zironi; S Siringo; A Rigamonti; C Barbara; W Grigioni; A Mazziotti Journal: Hepatology Date: 1992-07 Impact factor: 17.425
Authors: S Okada; N Okazaki; H Nose; K Aoki; N Kawano; J Yamamoto; K Shimada; T Takayama; T Kosuge; S Yamasaki Journal: Hepatogastroenterology Date: 1993-08
Authors: Sahil Mittal; Fasiha Kanwal; Jun Ying; Randy Chung; Yvonne H Sada; Sarah Temple; Jessica A Davila; Hashem B El-Serag Journal: J Hepatol Date: 2016-07-29 Impact factor: 25.083
Authors: Benjamin Yip; James M Wantuck; Lily H Kim; Robert J Wong; Aijaz Ahmed; Gabriel Garcia; Mindie H Nguyen Journal: Dig Dis Sci Date: 2013-11-27 Impact factor: 3.199
Authors: Leeyen Hsu; Christopher L Bowlus; Susan L Stewart; Tram Thanh Nguyen; Julie Dang; Brian Chan; Moon S Chen Journal: Dig Dis Sci Date: 2012-10-17 Impact factor: 3.199
Authors: Jessica A Davila; Jennifer R Kramer; Zhigang Duan; Peter A Richardson; Gia L Tyson; Yvonne H Sada; Fasiha Kanwal; Hashem B El-Serag Journal: Hepatology Date: 2013-03-14 Impact factor: 17.425